Table 2.
Variable | All | HCC (n=125, 38.0%) |
LC without HCC (n=204, 62.0%) |
p-value |
---|---|---|---|---|
Initial hemostasis achievement | 311 (94.5) | 115 (92.0) | 196 (96.1) | 0.114 |
Rebleeding | 191 (58.1) | 75 (60.0) | 116 (56.9) | 0.576 |
Treatment failure or rebleeding within 5 day | 33 (10.0) | 22 (17.6) | 11 (5.4) | <0.001 |
Rebleeding within 6 wk | 66 (20.1) | 37 (29.6) | 29 (14.2) | 0.001 |
Death | 186 (56.5) | 97 (77.6) | 89 (43.6) | <0.001 |
In hospital mortality | 40 (12.2) | 25 (20.0) | 15 (7.4) | 0.001 |
Mortality within 6 wk | 49 (14.9) | 33 (26.4) | 16 (7.8) | <0.001 |
PRBC transfusion, unit | 2 (1–4) | 2 (1–4) | 2 (1–4) | 0.363 |
FFP transfusion, unit | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.574 |
Cirrhosis-related complications | ||||
Hepatic failure | 26 (8.0) | 18 (14.5) | 8 (3.9) | 0.001 |
Hepatorenal syndrome | 16 (4.9) | 11 (8.9) | 5 (2.5) | 0.009 |
Hepatic encephalopathy | 43 (13.1) | 22 (17.7) | 21 (10.3) | 0.055 |
Hospital stay, day | 5 (3–9) | 6 (3–13) | 5 (3–8) | 0.001 |
Data are presented as number (%) or median (interquartile range).
HCC, hepatocellular carcinoma; LC, liver cirrhosis; PRBC, packed red blood cell; FFP, fresh frozen plasma.